All News

Found 123 articles

• Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference

  3/10/2022

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32nd Annual Healthcare Conference from March 15th to 17th.

• 

  Biopharma Companies Line Up Presentations Ahead of AACR Oncology Conference

  3/9/2022

  Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.

• Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022

  3/8/2022

  Gracell Biotechnologies Inc. announced the details of its poster presentation at the American Association for Cancer Research Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana.

• Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022

  3/2/2022

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on Monday, March 14, 2022.

• Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

  2/22/2022

  Gracell Biotechnologies Inc. today announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy at lower cost and with greater convenience.

• Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

  2/17/2022

  Gracell Biotechnologies Inc. today announced that it has dosed multiple patients in a clinical trial evaluating GC012F.

• Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit

  2/3/2022

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16th.

• Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

  1/18/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th.

• Gracell Biotechnologies Unveils Innovation Center in U.S.

  1/12/2022

  Gracell Biotechnologies Inc. announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022.

• Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index

  12/16/2021

  Gracell Biotechnologies Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

• Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan

  11/23/2021

  Gracell Biotechnologies Inc. today announced that members of its senior management team, including its Board and Chief Executive Officer Dr. William (Wei) Cao, Chief Financial Officer Dr. Yili Kevin Xie and Chief Medical Officer Dr. Martina A. Sersch, have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares ("ADSs") on the open market for an aggregate amount up to a maximum of $2 million within the next three months.

• Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma

  11/19/2021

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.

• Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/17/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update

  11/15/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights.

• Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting

  11/4/2021

  Gracell Biotechnologies Inc. announced preclinical data for GC502, an allogeneic chimeric antigen receptor T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology Annual Meeting and Exposition as part of the "Cellular Immunotherapies: Basic and Translational" session on December 11, 2021 from 5:30 p.m.-7:30 p.m..

• Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

  11/2/2021

  Gracell Biotechnologies Inc. today announced that it will participate in the following upcoming conferences: Goldman Sachs Asia Pacific Healthcare Forum 2021

• Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors

  10/20/2021

  Humanigen, Inc. announced today that the Company’s Board of Directors (the “Board”) has elected John Hohneker, MD, and Kevin Xie, PhD, to serve as independent directors of the Company, effective October 19, 2021.

• Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

  10/15/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences.

• Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

  8/26/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

• Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

  8/17/2021

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, reported its unaudited financial results for the second quarter of the year and recent business highlights.